Kevin Wood1, Thomas Hensing1, Raeva Malik2, Ravi Salgia3. 1. University of Chicago Medical Center, Chicago, Illinois. 2. George Washington University Medical Center, Washington, DC. 3. City of Hope Comprehensive Cancer Center, Duarte, California.
Abstract
IMPORTANCE: Lung cancer is the leading cause of cancer deaths worldwide, with non-small-cell lung cancer (NSCLC) constituting more than 80% of all lung cancers. Non-small-cell lung cancer is a heterogenous disease, with multiple different oncogenic driver mutations representing possible therapeutic targets. The vi-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) represents one of the most common oncogenic driver mutations. Unfortunately, targeted therapies thus far have been unsuccessful. OBJECTIVE: To discuss current advancements in understanding the prognostic and predictive value of KRAS in NSCLC and explaining the treatment advancements in both the preclinical and clinical setting. EVIDENCE REVIEW: PubMed, Cochrane Library, and Google Scholar databases were searched through February 1, 2016. English-language peer-reviewed articles published between 1964 and 2016 were found using the keywords "RAS," "KRAS," "NSCLC," "synthetic lethality," "oncogenic driver mutations," "clinical trials," and "phase 3 clinical trials." Abstracts at scientific meetings were not excluded. Of 112 records idetified, 61 articles or studies were included in qualitative synthesis for this review. FINDINGS: The KRAS oncogenic driver mutation is noted in 15% to 25% of patients with NSCLC. While there has been limited success in inhibiting the protein directly, phase 2 and phase 3 clinical trials have demonstrated success in inhibiting downstream effectors, specifically MEK1 and/or MEK2 with selumetinib and trametinib (albeit with poor tolerability). Current clinical trials are evaluating inhibiting downstream effector pathways for improved efficacy. In the laboratory, the success of synthetic lethal approaches suggests another possible direction for future clinical trials. CONCLUSIONS AND RELEVANCE: KRAS is one of the most common oncogenic driver mutations in NSCLC, with prior attempts at direct inhibition being unsuccessful. In recent years, there has been significant advancement in the understanding of the biology of KRAS and its downstream effectors. This has translated into a multitude of important preclinical studies and clinical trials that are currently underway to find effective therapeutic drugs for KRAS mutant lung cancer. Ultimately, better therapeutics need to be engineered to arrive at RAS-driven precision medicine.
IMPORTANCE: Lung cancer is the leading cause of cancer deaths worldwide, with non-small-cell lung cancer (NSCLC) constituting more than 80% of all lung cancers. Non-small-cell lung cancer is a heterogenous disease, with multiple different oncogenic driver mutations representing possible therapeutic targets. The vi-Ki-ras2 Kirsten ratsarcoma viral oncogene (KRAS) represents one of the most common oncogenic driver mutations. Unfortunately, targeted therapies thus far have been unsuccessful. OBJECTIVE: To discuss current advancements in understanding the prognostic and predictive value of KRAS in NSCLC and explaining the treatment advancements in both the preclinical and clinical setting. EVIDENCE REVIEW: PubMed, Cochrane Library, and Google Scholar databases were searched through February 1, 2016. English-language peer-reviewed articles published between 1964 and 2016 were found using the keywords "RAS," "KRAS," "NSCLC," "synthetic lethality," "oncogenic driver mutations," "clinical trials," and "phase 3 clinical trials." Abstracts at scientific meetings were not excluded. Of 112 records idetified, 61 articles or studies were included in qualitative synthesis for this review. FINDINGS: The KRAS oncogenic driver mutation is noted in 15% to 25% of patients with NSCLC. While there has been limited success in inhibiting the protein directly, phase 2 and phase 3 clinical trials have demonstrated success in inhibiting downstream effectors, specifically MEK1 and/or MEK2 with selumetinib and trametinib (albeit with poor tolerability). Current clinical trials are evaluating inhibiting downstream effector pathways for improved efficacy. In the laboratory, the success of synthetic lethal approaches suggests another possible direction for future clinical trials. CONCLUSIONS AND RELEVANCE: KRAS is one of the most common oncogenic driver mutations in NSCLC, with prior attempts at direct inhibition being unsuccessful. In recent years, there has been significant advancement in the understanding of the biology of KRAS and its downstream effectors. This has translated into a multitude of important preclinical studies and clinical trials that are currently underway to find effective therapeutic drugs for KRAS mutant lung cancer. Ultimately, better therapeutics need to be engineered to arrive at RAS-driven precision medicine.
Authors: I Sullivan; J Salazar; C Arqueros; M Andrés; A Sebio; M Majem; J Szafranska; E Martínez; D Páez; A López-Pousa; M Baiget; A Barnadas Journal: Clin Transl Oncol Date: 2017-02-01 Impact factor: 3.405
Authors: Pasi A Jänne; Michel M van den Heuvel; Fabrice Barlesi; Manuel Cobo; Julien Mazieres; Lucio Crinò; Sergey Orlov; Fiona Blackhall; Juergen Wolf; Pilar Garrido; Artem Poltoratskiy; Gabriella Mariani; Dana Ghiorghiu; Elaine Kilgour; Paul Smith; Alexander Kohlmann; David J Carlile; David Lawrence; Karin Bowen; Johan Vansteenkiste Journal: JAMA Date: 2017-05-09 Impact factor: 56.272
Authors: Shuai Li; Shengwu Liu; Jiehui Deng; Esra A Akbay; Josephine Hai; Chiara Ambrogio; Long Zhang; Fangyu Zhou; Russell W Jenkins; Dennis O Adeegbe; Peng Gao; Xiaoen Wang; Cloud P Paweletz; Grit S Herter-Sprie; Ting Chen; Laura Gutiérrez-Quiceno; Yanxi Zhang; Ashley A Merlino; Max M Quinn; Yu Zeng; Xiaoting Yu; Yuting Liu; Lichao Fan; Andrew J Aguirre; David A Barbie; Xianghua Yi; Kwok-Kin Wong Journal: Clin Cancer Res Date: 2018-06-26 Impact factor: 12.531
Authors: Mónica Garzón; Sergi Villatoro; Cristina Teixidó; Clara Mayo; Alejandro Martínez; Maria de Los Llanos Gil; Santiago Viteri; Daniela Morales-Espinosa; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-10
Authors: Julie G Fisher; David Tait; Elizabeth Garrett-Mayer; Susan Halabi; Pam K Mangat; Julian C Schink; Ricardo H Alvarez; Dan Veljovich; Timothy L Cannon; Pamela A Crilley; Theodore Pollock; Carmen J Calfa; Tareq Al Baghdadi; Ramya Thota; Nicole Fleming; Jared A Cotta; Andrew L Rygiel; Sasha L Warren; Richard L Schilsky Journal: Target Oncol Date: 2020-12 Impact factor: 4.493
Authors: Ismail M Meraz; Mourad Majidi; Xiaobo Cao; Heather Lin; Lerong Li; Jing Wang; Veera Baladandayuthapani; David Rice; Boris Sepesi; Lin Ji; Jack A Roth Journal: Cancer Immunol Res Date: 2018-01-16 Impact factor: 11.151